電子臨床転帰評価 (eCOA) ソリューション市場 : 2029年までの世界予測

Report Overview

The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% during the forecast period.

電子臨床転帰評価 (eCOA) ソリューション市場は、2024 年の 18 億米ドルから 2029 年までに 39 億米ドルに達すると予測されており、予測期間中の CAGR は 16.6% です。

The the growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market.  On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period. 

“The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices.”
The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials.

“Clinical trials segment is estimated to hold the largest share of electronic clinical outcome assessment (eCOA) solutions market, by application.”
Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research.

“Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by  product type segment.”
Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment.

“Asia Pacific to register the highest growth in the electronic clinical outcome assessment (eCOA) solutions market in the forecast period.”
The global electronic clinical outcome assessment (eCOA) solutions market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, Asia Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population,  increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia Pacific.

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:
•     By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company’s Product managers, Purchase Heads, etc. (35%), and Others (25%).
•     By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)
•     By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)

The prominent players in this market are Koninklijke Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), Merative (US), ICON plc (Ireland), Paraxel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC. (US), Clinical ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage
• The report studies the electronic clinical outcome assessment (eCOA) solutions market based on component, product type, deployment model, application area, end user, and region. 
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total electronic clinical outcome assessment (eCOA) solutions market.
• The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:
n Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market.
n Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market.
n Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions solutions across regions.
n Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market.
n Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.

Table of Contents

1            INTRODUCTION            58

1.1         STUDY OBJECTIVES      58

1.2         MARKET DEFINITION   58

1.2.1      INCLUSIONS & EXCLUSIONS     59

1.3         MARKET SCOPE             60

1.3.1      MARKET SEGMENTATION         60

FIGURE 1           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SEGMENTATION 60

1.3.2      REGIONAL SCOPE         61

1.4         YEARS CONSIDERED     61

1.4.1      CURRENCY CONSIDERED          62

TABLE 1             EXCHANGE RATES UTILIZED FOR CONVERSION TO USD              62

1.5         STAKEHOLDERS            62

1.6         RECESSION IMPACT      62

2            RESEARCH METHODOLOGY     63

2.1         RESEARCH DATA           63

FIGURE 2           RESEARCH DESIGN       63

2.2         SECONDARY SOURCES 64

2.2.1      KEY DATA FROM SECONDARY SOURCES            65

2.3         PRIMARY DATA 65

2.3.1      PRIMARY SOURCES       66

2.3.1.1   Key data from primary sources         67

2.3.1.2   Key industry insights          68

2.3.2      BREAKDOWN OF PRIMARY INTERVIEWS            68

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION    68

2.4         RESEARCH METHODOLOGY DESIGN    69

FIGURE 4           RESEARCH METHODOLOGY: HYPOTHESIS BUILDING  69

2.5         MARKET SIZE ESTIMATION       69

FIGURE 5           SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS          70

2.5.1      BOTTOM-UP APPROACH           71

FIGURE 6           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: BOTTOM-UP APPROACH             71

FIGURE 7           DEMAND-SIDE APPROACH: END-USER SPENDING ON ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS  72

2.5.2      TOP-DOWN APPROACH             72

FIGURE 8           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: TOP-DOWN APPROACH 73

TABLE 2             FACTOR ANALYSIS        74

FIGURE 9           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       75

FIGURE 10         CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   76

2.6         MARKET BREAKDOWN & DATA TRIANGULATION          77

FIGURE 11         DATA TRIANGULATION METHODOLOGY         77

2.7         ASSUMPTIONS 78

2.7.1      MARKET SIZING ASSUMPTIONS             78

2.7.2      OVERALL STUDY ASSUMPTIONS            78

2.8         LIMITATIONS   79

2.8.1      SCOPE-RELATED LIMITATIONS             79

2.8.2      METHODOLOGY-RELATED LIMITATIONS         79

2.9         RISK ASSESSMENT         79

TABLE 3             ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RISK ASSESSMENT           79

2.10       ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RECESSION IMPACT ANALYSIS            79

TABLE 4             GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)         79

TABLE 5             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  80

TABLE 6             US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)  80

3            EXECUTIVE SUMMARY 81

FIGURE 12         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2024 VS. 2029 (USD MILLION) 81

FIGURE 13         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2024 VS. 2029 (USD MILLION)        82

FIGURE 14         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2024 VS. 2029 (USD MILLION)      83

FIGURE 15         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)          84

FIGURE 16         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2024 VS. 2029 (USD MILLION)              84

FIGURE 17         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)     85

FIGURE 18         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2024 VS. 2029 (USD MILLION)      86

FIGURE 19         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT            87

4            PREMIUM INSIGHTS      88

4.1         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET OVERVIEW     88

FIGURE 20         GOVERNMENT INITIATIVES & SURGING R&D EXPENDITURES TO DRIVE MARKET GROWTH   88

4.2         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT AND COUNTRY (2023)       89

FIGURE 21         JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC  MARKET IN 2023             89

4.3         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES      90

FIGURE 22         CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       90

4.4         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL MIX (2021−2029)  91

FIGURE 23         NORTH AMERICA TO CONTINUE TO DOMINATE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET DURING FORECAST PERIOD       91

4.5         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEVELOPED VS. EMERGING ECONOMIES       92

FIGURE 24         EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD       92

5            MARKET OVERVIEW     93

5.1         INTRODUCTION            93

5.2         MARKET DYNAMICS     93

FIGURE 25         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES   93

5.2.1      MARKET DYNAMICS: IMPACT ANALYSIS             94

5.2.2      DRIVERS            95

5.2.2.1   Increasing R&D expenditure for product development by medtech and pharma-biotech companies             95

FIGURE 26         INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028          95

5.2.2.2   Rising operational costs and regulatory requirements associated with clinical research studies   96

5.2.2.3   Favorable government support and funding for clinical trials      96

5.2.2.4   Growing prevalence of chronic diseases & subsequent increase in clinical trials              97

5.2.2.5   Effective monitoring of clinical data 98

5.2.2.6   Reduction in overall costs and timelines of clinical trials             98

5.2.3      RESTRAINTS     98

5.2.3.1   Dearth of skilled professionals to develop and operate eCOA solutions    98

5.2.3.2   High implementation and maintenance costs 99

5.2.3.3   Lack of awareness about eCOA solutions among end users        99

5.2.4      OPPORTUNITIES           100

5.2.4.1   Surging eCOA adoption owing to increasing number of clinical trials in emerging economies           100

5.2.4.2   Growing outsourcing of clinical trial processes to CROs             100

5.2.4.3   Gradual shift from manual data interpretation to real-time data analysis  101

5.2.4.4   Growing penetration of mobile technology in healthcare industry            102

5.2.5      CHALLENGES   102

5.2.5.1   Evolving regulatory landscape and compliance requirements     102

5.2.5.2   Concerns regarding data security & privacy   103

5.2.5.3   Lack of interoperability & integration            104

5.2.5.4   Resistance from traditional healthcare professionals and concerns regarding software reliability             104

6            INDUSTRY INSIGHTS    106

6.1         INTRODUCTION            106

6.2         OVERVIEW OF KEY INDUSTRY TRENDS 106

6.2.1      RISING NUMBER OF DECENTRALIZED CLINICAL TRIALS            106

6.2.2      INCREASED FOCUS ON REAL-WORLD DATA (RWD)       107

6.3         VALUE/SUPPLY CHAIN ANALYSIS          108

FIGURE 27         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: VALUE CHAIN ANALYSIS (2023)  108

6.4         ECOSYSTEM ANALYSIS 109

FIGURE 28         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: ECOSYSTEM ANALYSIS (2023)     109

6.5         TECHNOLOGY ANALYSIS           109

6.5.1      KEY TECHNOLOGIES    109

6.5.1.1   Machine learning 109

6.5.1.2   Artificial intelligence          110

6.5.1.3   Internet of things 110

6.5.1.4   Integrated APIs   110

6.5.2      COMPLEMENTARY TECHNOLOGIES     111

6.5.2.1   Interactive Voice Response (IVR)    111

6.5.2.2   Data analytics      111

6.5.2.3   Telehealth           111

6.5.3      ADJACENT TECHNOLOGIES      112

6.5.3.1   Cloud computing 112

6.5.3.2   Blockchain           112

6.6         REGULATORY LANDSCAPE       112

6.6.1      REGULATORY ANALYSIS            112

6.6.1.1   North America     112

6.6.1.2   Europe  114

6.6.1.3   Asia Pacific          114

6.6.1.4   Latin America      115

6.6.1.5   Middle East & Africa          115

6.6.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          116

TABLE 7             NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         116

TABLE 8             EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116

TABLE 9             ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         117

TABLE 10           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         117

6.7         PORTER’S FIVE FORCES ANALYSIS         118

TABLE 11           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PORTER’S FIVE FORCES ANALYSIS           118

6.7.1      COMPETITIVE RIVALRY             119

6.7.2      BARGAINING POWER OF BUYERS           119

6.7.3      BARGAINING POWER OF SUPPLIERS     119

6.7.4      THREAT OF SUBSTITUTES         119

6.7.5      THREAT OF NEW ENTRANTS    119

6.8         PRICING ANALYSIS        120

6.8.1      AVERAGE SELLING PRICE TREND, BY REGION  121

6.8.2      INDICATIVE PRICING ANALYSIS, BY PRODUCT 121

TABLE 12           AVERAGE SELLING PRICE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS, BY SOLUTION TYPE (2023)              121

6.9         CASE STUDY ANALYSIS 122

6.9.1      CASE 1: A LEADING ACADEMIC MEDICAL CENTER MONITORS NEWLY DIAGNOSED MYELOMA PATIENTS WITH MEDIDATA ECOA       122

6.9.2      CASE 2: SIGNANT’S SCALE MANAGEMENT EXPERTISE FACILITATES ENDPOINT ACCURACY & RELIABILITY IN PSORIATIC ARTHRITIS TRIAL              123

6.10       PATENT ANALYSIS        124

FIGURE 29         TOP PATENT OWNERS AND APPLICANTS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS (JANUARY 2011–JANUARY 2024) 125

FIGURE 30         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PATENT ANALYSIS (JANUARY 2011–JANUARY 2024)              126

FIGURE 31         TOP APPLICANT COUNTRIES/REGIONS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTION PATENTS (JANUARY 2011–JANUARY 2024)     126

TABLE 13           LIST OF PATENTS/PATENT APPLICATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, 2021–2023              127

6.11       KEY CONFERENCES & EVENTS, 2023–2024           128

TABLE 14           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES & EVENTS     128

6.12       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 129

FIGURE 32         REVENUE SHIFT IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET       129

6.13       KEY STAKEHOLDERS & BUYING CRITERIA          130

6.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         130

FIGURE 33         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS          130

TABLE 15           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS             130

6.13.2    BUYING CRITERIA         131

FIGURE 34         KEY BUYING CRITERIA FOR END USERS              131

TABLE 16           KEY BUYING CRITERIA FOR END USERS              131

6.14       END-USER ANALYSIS    131

6.14.1    UNMET NEEDS 131

TABLE 17           UNMET NEEDS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA)  SOLUTIONS MARKET    132

6.14.2    END-USER EXPECTATIONS       133

TABLE 18           END-USER EXPECTATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET 133

6.15       REVENUE MODEL ANALYSIS     133

6.15.1    SUBSCRIPTION-BASED MODEL 133

6.15.2    PAY-PER-STUDY MODEL           134

6.15.3    CUSTOMIZED SOLUTIONS MODEL       134

6.15.4    SOFTWARE-AS-A-SERVICE (SAAS) MODEL          134

6.15.5    CONSULTING AND INTEGRATION SERVICES MODEL    134

6.16       INVESTMENT LANDSCAPE        135

FIGURE 35         RECENT INVESTMENTS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET       135

7            ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT        136

7.1         INTRODUCTION            137

TABLE 19           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)     137

TABLE 20           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)     137

7.2         SOFTWARE       138

7.2.1      ADVANTAGES OF ECOA SOFTWARE LIKE REAL-TIME ANALYSIS AND STREAMLINED DATA COLLECTION TO FOSTER MARKET GROWTH      138

TABLE 21           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2022 (USD MILLION)          139

TABLE 22           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2029 (USD MILLION)          140

7.3         SERVICES          140

7.3.1      ABILITY OF ECOA SERVICES TO REDUCE TIME AND COST OF CLINICAL TRIAL PROCESSES TO BOOST DEMAND             140

TABLE 23           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2018–2022 (USD MILLION)              141

TABLE 24           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2023–2029 (USD MILLION)              142

7.4         WEARABLES, MOBILE DEVICES, AND OTHER DEVICES  142

TABLE 25           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          143

TABLE 26           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          143

TABLE 27           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY,  2018–2022 (USD MILLION)      144

TABLE 28           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY,  2023–2029 (USD MILLION)      145

7.4.1      BRING YOUR OWN DEVICE (BYOD) MODEL      145

7.4.1.1   Ability of BYOD models to increase flexibility and convenience to drive adoption              145

TABLE 29           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2018–2022 (USD MILLION)    146

TABLE 30           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2023–2029 (USD MILLION)    147

7.4.2      PROVISIONED DEVICE MODEL 147

7.4.2.1   Growing need for standardization and control in data collection process to support market growth     147

TABLE 31           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2018–2022 (USD MILLION)          148

TABLE 32           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2023–2029 (USD MILLION)          149

7.4.3      HYBRID MODEL             149

7.4.3.1   Ability of hybrid models to increase balance between standardization and participant preferences to favor growth          149

TABLE 33           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2018–2022 (USD MILLION)          150

TABLE 34           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2023–2029 (USD MILLION)          151

8            ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT 152

8.1         INTRODUCTION            153

TABLE 35           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)           153

TABLE 36           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)           154

8.2         ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO)             154

8.2.1      GROWING EMPHASIS ON PATIENT-CENTRIC HEALTHCARE TO BOOST MARKET GROWTH        154

TABLE 37           ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY,  2018–2022 (USD MILLION)      155

TABLE 38           ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY,  2023–2029 (USD MILLION)      156

8.3         ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO)     156

8.3.1      GROWING NEED FOR ACCURATE AND RELIABLE DATA COLLECTION TO DRIVE ADOPTION OF EOBSRO SOLUTIONS 156

TABLE 39           ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY,  2018–2022 (USD MILLION)      157

TABLE 40           ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY,  2023–2029 (USD MILLION)      158

8.4         ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO)   158

8.4.1      INCREASING EFFICACY AND ACCURACY IN CAPTURING CLINICIAN-REPORTED DATA TO PROPEL GROWTH            158

TABLE 41           ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY,  2018–2022 (USD MILLION)      159

TABLE 42           ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY,  2023–2029 (USD MILLION)      160

8.5         ELECTRONIC PERFORMANCE-REPORTED OUTCOME (EPERFO)              160

8.5.1      INCREASING ACCESSIBILITY AND FLEXIBILITY IN CLINICAL TRIAL SETTINGS TO BOOST MARKET 160

TABLE 43           ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2018–2022 (USD MILLION)    161

TABLE 44           ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2023–2029 (USD MILLION)    162

9            ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL      163

9.1         INTRODUCTION            164

TABLE 45           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)              164

TABLE 46           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)              164

9.2         ON-PREMISE MODEL    164

9.2.1      OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE      164

TABLE 47           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2018–2022 (USD MILLION)          165

TABLE 48           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2023–2029 (USD MILLION)          166

9.3         WEB-HOSTED & CLOUD-BASED MODEL            166

9.3.1      ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET      166

TABLE 49           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2018–2022 (USD MILLION)       167

TABLE 50           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2023–2029 (USD MILLION)       168

9.4         HYBRID MODEL             168

9.4.1      ABILITY TO OFFER BALANCED SOLUTIONS USING HYBRID MODEL  TO SUPPORT MARKET GROWTH           168

TABLE 51           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2018–2022 (USD MILLION)          169

TABLE 52           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2023–2029 (USD MILLION)          170

10          ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION       171

10.1       INTRODUCTION            172

TABLE 53           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)     172

TABLE 54           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)     172

10.2       CLINICAL TRIALS          173

TABLE 55           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)              173

TABLE 56           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY THERAPEUTIC AREAS, 2023–2029 (USD MILLION)              174

TABLE 57           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2018–2022 (USD MILLION)          174

TABLE 58           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2023–2029 (USD MILLION)          175

10.2.1    ONCOLOGY      176

10.2.1.1 Rising incidence of cancer to drive market growth        176

FIGURE 36         US: CANCER INCIDENCE IN MALES, BY TYPE (2022)       176

FIGURE 37         US: CANCER INCIDENCE IN FEMALES, BY TYPE (2022)   176

FIGURE 38         GLOBAL ONCOLOGY CLINICAL TRIALS, 2010–2021 (THOUSAND)   177

TABLE 59           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)          178

TABLE 60           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)          179

10.2.2    INFECTIOUS DISEASES 179

10.2.2.1 Growing focus on infectious disease treatment and management to boost market              179

TABLE 61           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2022 (USD MILLION) 180

TABLE 62           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 181

10.2.3    NEUROLOGY    181

10.2.3.1 Increasing investments in R&D and grants for neurological disorders to drive market   181

TABLE 63           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2022 (USD MILLION)          182

TABLE 64           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2029 (USD MILLION)          183

10.2.4    METABOLIC DISORDERS           183

10.2.4.1 Rising diabetes incidence to drive market      183

FIGURE 39         INCREASE IN DIABETES CASES, 2000–2045 (MILLION INDIVIDUALS)  184

TABLE 65           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION) 184

TABLE 66           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 185

10.2.5    IMMUNOLOGY 185

10.2.5.1 Increasing development of immunology drugs to drive demand for eCOA solutions              185

TABLE 67           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)          186

TABLE 68           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)          187

10.2.6    CARDIOVASCULAR DISEASES   187

10.2.6.1 Need for efficient and reliable means of collecting patient-reported outcomes in cardiovascular trials to support growth           187

TABLE 69           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018–2022 (USD MILLION)     188

TABLE 70           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)     189

10.2.7    RARE DISEASES & GENETIC DISORDERS             189

10.2.7.1 Growing government support for rare diseases & genetic disorders to boost market              189

TABLE 71           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION)    190

TABLE 72           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)    191

10.2.8    MENTAL HEALTH DISORDERS  191

10.2.8.1 Growing awareness of mental health disorders to contribute to market growth              191

TABLE 73           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION)     192

TABLE 74           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)     193

10.2.9    OTHER THERAPEUTIC AREAS   193

TABLE 75           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018–2022 (USD MILLION)     194

TABLE 76           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2029 (USD MILLION)     195

10.3       OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION   195

10.3.1    GROWING RECOGNITION OF BENEFITS OF REAL-WORLD EVIDENCE GENERATION TO DRIVE DEMAND         195

TABLE 77           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2018–2022 (USD MILLION)              196

TABLE 78           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY,  2023–2029 (USD MILLION)              197

10.4       PATIENT MANAGEMENT & REGISTRIES 197

10.4.1    EVOLVING LANDSCAPE OF PATIENT-CENTRIC HEALTHCARE TO DRIVE SEGMENTAL GROWTH  197

TABLE 79           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2018–2022 (USD MILLION)    198

TABLE 80           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2023–2029 (USD MILLION)    199

10.5       OTHER APPLICATIONS 199

TABLE 81           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR  OTHER APPLICATIONS, BY COUNTRY, 2018–2022 (USD MILLION) 200

TABLE 82           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2029 (USD MILLION) 201

11          ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER 202

11.1       INTRODUCTION            203

TABLE 83           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION) 203

TABLE 84           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)            204

11.2       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   204

11.2.1    INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET      204

TABLE 85           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,  2018–2022 (USD MILLION) 205

TABLE 86           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,  2023–2029 (USD MILLION) 206

11.3       CONTRACT RESEARCH ORGANIZATIONS (CROS)           206

11.3.1    RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS  BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET     206

TABLE 87           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY,  2018–2022 (USD MILLION)         207

TABLE 88           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY,  2023–2029 (USD MILLION)         208

11.4       GOVERNMENT ORGANIZATIONS           208

11.4.1    GROWING COLLABORATIONS BETWEEN GOVERNMENT ORGANIZATIONS AND CROS TO PROPEL GROWTH       208

TABLE 89           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2018–2022 (USD MILLION)          209

TABLE 90           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2023–2029 (USD MILLION)          210

11.5       MEDTECH COMPANIES 210

11.5.1    GROWING UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL GROWTH         210

TABLE 91           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION) 211

TABLE 92           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION) 212

11.6       HOSPITALS & HEALTHCARE PROVIDERS            212

11.6.1    INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET GROWTH      212

TABLE 93           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2018–2022 (USD MILLION)    213

TABLE 94           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2023–2029 (USD MILLION)    214

11.7       ACADEMIC & RESEARCH INSTITUTES   214

11.7.1    FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH    214

TABLE 95           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2022 (USD MILLION)          215

TABLE 96           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2029 (USD MILLION)          216

11.8       CONSULTING SERVICE COMPANIES      216

11.8.1    GROWING COLLABORATIONS BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET  216

TABLE 97           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)          217

TABLE 98           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)          218

12          ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION    219

12.1       INTRODUCTION            220

TABLE 99           ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018–2022 (USD MILLION)    220

TABLE 100         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY REGION, 2023–2029 (USD MILLION) 220

12.2       NORTH AMERICA          221

FIGURE 40         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT 222

TABLE 101         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)          223

TABLE 102         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)          223

TABLE 103         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          223

TABLE 104         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          224

TABLE 105         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)              224

TABLE 106         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)              224

TABLE 107         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          225

TABLE 108         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          225

TABLE 109         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     226

TABLE 110         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     226

TABLE 111         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          226

TABLE 112         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          227

TABLE 113         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)             227

TABLE 114         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)             228

TABLE 115         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          228

TABLE 116         NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          229

12.2.1    NORTH AMERICA: RECESSION IMPACT 229

12.2.2    US         230

12.2.2.1 Rising government funding for pharmaceutical R&D  to drive market    230

FIGURE 41         DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)  230

TABLE 117         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)     231

TABLE 118         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)     231

TABLE 119         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          232

TABLE 120         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          232

TABLE 121         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)           233

TABLE 122         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)           233

TABLE 123         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)              234

TABLE 124         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)              234

TABLE 125         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)     234

TABLE 126         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)     235

TABLE 127         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)     235

TABLE 128         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)     236

TABLE 129         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)            236

TABLE 130         US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)            237

12.2.3    CANADA            237

12.2.3.1 Increasing number of clinical trials to support market growth     237

TABLE 131         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)              238

TABLE 132         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)              238

TABLE 133         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          238

TABLE 134         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          239

TABLE 135         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION) 239

TABLE 136         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 240

TABLE 137         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          240

TABLE 138         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          241

TABLE 139         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)              241

TABLE 140         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)              242

TABLE 141         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          242

TABLE 142         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          243

TABLE 143         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION) 243

TABLE 144         CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION) 244

12.3       EUROPE             244

TABLE 145         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COUNTRY, 2018–2022 (USD MILLION)              245

TABLE 146         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COUNTRY, 2023–2029 (USD MILLION)              245

TABLE 147         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              246

TABLE 148         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              246

TABLE 149         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          246

TABLE 150         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          247

TABLE 151         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              247

TABLE 152         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)              248

TABLE 153         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          248

TABLE 154         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          249

TABLE 155         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              249

TABLE 156         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              250

TABLE 157         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          250

TABLE 158         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          251

TABLE 159         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              251

TABLE 160         EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION) 252

12.3.1    EUROPE: RECESSION IMPACT   252

12.3.2    GERMANY         253

12.3.2.1 Increase in R&D expenditure and clinical trials to boost market growth   253

TABLE 161         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)              253

TABLE 162         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)              254

TABLE 163         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          254

TABLE 164         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          254

TABLE 165         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION) 255

TABLE 166         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 255

TABLE 167         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          256

TABLE 168         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          256

TABLE 169         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)              256

TABLE 170         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)              257

TABLE 171         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          257

TABLE 172         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          258

TABLE 173         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION) 258

TABLE 174         GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION) 259

12.3.3    UK         259

12.3.3.1 Growing investments in drug discovery services to favor market growth   259

TABLE 175         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)     260

TABLE 176         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)     260

TABLE 177         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          261

TABLE 178         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          261

TABLE 179         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)           262

TABLE 180         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)           262

TABLE 181         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)              263

TABLE 182         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)              263

TABLE 183         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)     263

TABLE 184         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)     264

TABLE 185         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET  FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)     264

TABLE 186         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)     265

TABLE 187         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)            265

TABLE 188         UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION) 266

12.3.4    FRANCE             266

12.3.4.1 Growing R&D pipeline for oncology trials to drive market         266

TABLE 189         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              267

TABLE 190         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              267

TABLE 191         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          268

TABLE 192         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          268

TABLE 193         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              269

TABLE 194         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)              269

TABLE 195         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          270

TABLE 196         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          270

TABLE 197         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              270

TABLE 198         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              271

TABLE 199         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          271

TABLE 200         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          272

TABLE 201         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              272

TABLE 202         FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION) 273

12.3.5    ITALY   273

12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake              273

TABLE 203         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              274

TABLE 204         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              274

TABLE 205         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          274

TABLE 206         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          275

TABLE 207         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              275

TABLE 208         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)              276

TABLE 209         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          276

TABLE 210         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          277

TABLE 211         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              277

TABLE 212         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              278

TABLE 213         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          278

TABLE 214         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          279

TABLE 215         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              279

TABLE 216         ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)              280

12.3.6    REST OF EUROPE           280

TABLE 217         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          281

TABLE 218         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          281

TABLE 219         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)              282

TABLE 220         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)              282

TABLE 221         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          283

TABLE 222         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          283

TABLE 223         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     284

TABLE 224         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     284

TABLE 225         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          284

TABLE 226         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          285

TABLE 227         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)             285

TABLE 228         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)             286

TABLE 229         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          286

TABLE 230         REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          287

12.4       ASIA PACIFIC    287

FIGURE 42         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT 289

TABLE 231         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)          290

TABLE 232         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)          290

TABLE 233         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          290

TABLE 234         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          291

TABLE 235         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)              291

TABLE 236         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)              291

TABLE 237         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          292

TABLE 238         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          292

TABLE 239         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     293

TABLE 240         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     293

TABLE 241         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          293

TABLE 242         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          294

TABLE 243         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)             294

TABLE 244         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)             295

TABLE 245         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          295

TABLE 246         ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          296

12.4.1    ASIA PACIFIC: RECESSION IMPACT        296

12.4.2    JAPAN  297

12.4.2.1 Established clinical trial infrastructure and increase in funds for R&D to support growth   297

TABLE 247         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              297

TABLE 248         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              298

TABLE 249         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          298

TABLE 250         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          298

TABLE 251         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              299

TABLE 252         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)              299

TABLE 253         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          300

TABLE 254         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          300

TABLE 255         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              300

TABLE 256         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              301

TABLE 257         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          301

TABLE 258         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          302

TABLE 259         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              302

TABLE 260         JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)              303

12.4.3    CHINA  303

12.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market              303

TABLE 261         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              304

TABLE 262         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              304

TABLE 263         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          305

TABLE 264         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          305

TABLE 265         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              306

TABLE 266         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2023–2029 (USD MILLION)              306

TABLE 267         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          307

TABLE 268         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          307

TABLE 269         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              307

TABLE 270         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              308

TABLE 271         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          308

TABLE 272         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          309

TABLE 273         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              309

TABLE 274         CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)              310

12.4.4    INDIA   310

12.4.4.1 Growing pharmaceutical industry to fuel uptake of eCOA solutions         310

TABLE 275         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2018–2022 (USD MILLION)              311

TABLE 276         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY COMPONENT, 2023–2029 (USD MILLION)              311

TABLE 277         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)          312

TABLE 278         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)          312

TABLE 279         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY PRODUCT, 2018–2022 (USD MILLION)              313

TABLE 280         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 313

TABLE 281         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)          314

TABLE 282         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)          314

TABLE 283         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2018–2022 (USD MILLION)              314

TABLE 284         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY APPLICATION, 2023–2029 (USD MILLION)              315

TABLE 285         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)          315

TABLE 286         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)          316

TABLE 287         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2018–2022 (USD MILLION)              316

TABLE 288         INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET,  BY END USER, 2023–2029 (USD MILLION)              317

12.4.5    REST OF ASIA PACIFIC  317

TABLE 289         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          318

TABLE 290         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          318

TABLE 291         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES,  BY MODEL, 2018–2022 (USD MILLION)              318

TABLE 292         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES,  BY MODEL, 2023–2029 (USD MILLION)              319

TABLE 293         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          319

TABLE 294         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          320

TABLE 295         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     320

TABLE 296         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     321

TABLE 297         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          321

TABLE 298         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          322

TABLE 299         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2018–2022 (USD MILLION)           322

TABLE 300         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2023–2029 (USD MILLION)           323

TABLE 301         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          323

TABLE 302         REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          324

12.5       LATIN AMERICA             324

12.5.1    LARGE POOL OF PHARMACEUTICAL COMPANIES TO FAVOR MARKET GROWTH          324

TABLE 303         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          325

TABLE 304         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          325

TABLE 305         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2018–2022 (USD MILLION)              326

TABLE 306         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)              326

TABLE 307         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          327

TABLE 308         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          327

TABLE 309         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     328

TABLE 310         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     328

TABLE 311         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          328

TABLE 312         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          329

TABLE 313         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)             329

TABLE 314         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)             330

TABLE 315         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          330

TABLE 316         LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          331

12.5.2    LATIN AMERICA: RECESSION IMPACT   331

12.6       MIDDLE EAST & AFRICA             332

TABLE 317         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018–2022 (USD MILLION)          332

TABLE 318         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)          332

TABLE 319         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          333

TABLE 320         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          333

TABLE 321         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES,  BY MODEL, 2018–2022 (USD MILLION)              333

TABLE 322         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023–2029 (USD MILLION) 334

TABLE 323         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          334

TABLE 324         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          335

TABLE 325         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     335

TABLE 326         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     336

TABLE 327         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          336

TABLE 328         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          337

TABLE 329         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2018–2022 (USD MILLION)           337

TABLE 330         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2023–2029 (USD MILLION)           338

TABLE 331         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          338

TABLE 332         MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          339

12.6.1    MIDDLE EAST & AFRICA: RECESSION IMPACT   339

12.6.2    GCC COUNTRIES           340

12.6.2.1 Increase in healthcare investments to support market growth     340

TABLE 333         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)          341

TABLE 334         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)          341

TABLE 335         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018–2022 (USD MILLION) 341

TABLE 336         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL,  2023–2029 (USD MILLION)              342

TABLE 337         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)          342

TABLE 338         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)          343

TABLE 339         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)     343

TABLE 340         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)     344

TABLE 341         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          344

TABLE 342         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          345

TABLE 343         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)             345

TABLE 344         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)             346

TABLE 345         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)          346

TABLE 346         GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)          347

12.6.3    REST OF MIDDLE EAST & AFRICA           347

TABLE 347         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)     348

TABLE 348         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)     348

TABLE 349         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES,  BY MODEL, 2018–2022 (USD MILLION)          349

TABLE 350         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES,  BY MODEL, 2023–2029 (USD MILLION)          349

TABLE 351         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)     350

TABLE 352         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)     350

TABLE 353         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)        351

TABLE 354         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)        351

TABLE 355         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)          351

TABLE 356         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)          352

TABLE 357         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2018–2022 (USD MILLION)     352

TABLE 358         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA,  2023–2029 (USD MILLION)     353

TABLE 359         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)     353

TABLE 360         REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)     354

13          COMPETITIVE LANDSCAPE       355

13.1       OVERVIEW        355

13.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          355

TABLE 361         OVERVIEW OF STRATEGIES DEPLOYED BY KEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET VENDORS              356

13.3       REVENUE ANALYSIS      357

FIGURE 43         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS (2018–2022)              358

13.4       MARKET SHARE ANALYSIS         358

FIGURE 44         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: MARKET SHARE ANALYSIS (2023)             358

TABLE 362         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEGREE OF COMPETITION         359

13.5       BRAND/SOFTWARE COMPARATIVE ANALYSIS  360

13.5.1    MEDIDATA (US)             360

13.5.2    IQVIA (US)         361

13.5.3    ICON PLC (IRELAND)   361

13.5.4    SIGNANT HEALTH (US) 361

13.5.5    CLARIO (US)     361

13.6       VALUATION AND FINANCIAL METRICS OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS VENDORS            362

FIGURE 45         EV/EBITDA OF KEY VENDORS   362

FIGURE 46         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF  KEY VENDORS           362

13.7       COMPANY EVALUATION MATRIX: KEY PLAYERS            363

13.7.1    STARS  363

13.7.2    EMERGING LEADERS    363

13.7.3    PERVASIVE PLAYERS     363

13.7.4    PARTICIPANTS 363

FIGURE 47         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023              364

13.7.5    COMPANY FOOTPRINT ANALYSIS         365

FIGURE 48         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY FOOTPRINT  365

TABLE 363         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPONENT FOOTPRINT          366

TABLE 364         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEPLOYMENT MODEL FOOTPRINT        367

TABLE 365         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: END-USER FOOTPRINT  368

TABLE 366         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL FOOTPRINT 369

13.8       COMPANY EVALUATION MATRIX: STARTUPS/SMES      370

13.8.1    PROGRESSIVE COMPANIES       370

13.8.2    DYNAMIC COMPANIES 370

13.8.3    RESPONSIVE COMPANIES          370

13.8.4    STARTING BLOCKS       370

FIGURE 49         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023     371

13.8.5    COMPETITIVE BENCHMARKING            372

TABLE 367         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DETAILED LIST OF KEY SMES/STARTUPS       372

TABLE 368         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)        373

13.9       COMPETITIVE SCENARIO          374

TABLE 369         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021–NOVEMBER 2023            374

TABLE 370         ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEALS, JANUARY 2021–NOVEMBER 2023  375

14          COMPANY PROFILES    376

(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*

14.1       KEY PLAYERS   376

14.1.1    MEDIDATA (A DASSAULT SYSTÈMES COMPANY)           376

TABLE 371         MEDIDATA: COMPANY OVERVIEW        376

FIGURE 50         DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2022)     377

TABLE 372         MEDIDATA: PRODUCTS/SOLUTIONS/SERVICES OFFERED              377

TABLE 373         MEDIDATA: PRODUCT/SERVICE LAUNCHES     378

TABLE 374         MEDIDATA: DEALS       378

14.1.2    IQVIA   380

TABLE 375         IQVIA: COMPANY OVERVIEW    380

FIGURE 51         IQVIA: COMPANY SNAPSHOT (2022)      381

TABLE 376         IQVIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED     381

14.1.3    SIGNANT HEALTH        383

TABLE 377         SIGNANT HEALTH: COMPANY OVERVIEW         383

TABLE 378         SIGNANT HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED          383

TABLE 379         SIGNANT HEALTH: PRODUCT/SERVICE LAUNCHES & UPGRADES       384

TABLE 380         SIGNANT HEALTH: DEALS         384

14.1.4    CLARIO 386

TABLE 381         CLARIO: COMPANY OVERVIEW 386

TABLE 382         CLARIO: PRODUCTS/SOLUTIONS/SERVICES OFFERED 386

TABLE 383         CLARIO: DEALS 387

14.1.5    ICON PLC          389

TABLE 384         ICON PLC: COMPANY OVERVIEW           389

FIGURE 52         ICON PLC: COMPANY SNAPSHOT (2022)             390

TABLE 385         ICON PLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED              390

TABLE 386         ICON PLC: PRODUCT/SERVICE LAUNCHES        391

TABLE 387         ICON PLC: DEALS          391

14.1.6    ORACLE CORPORATION            393

TABLE 388         ORACLE CORPORATION: COMPANY OVERVIEW             393

FIGURE 53         ORACLE CORPORATION: COMPANY SNAPSHOT (2022) 394

TABLE 389         ORACLE CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED          394

TABLE 390         ORACLE CORPORATION: DEALS            395

14.1.7    MEDABLE INC. 396

TABLE 391         MEDABLE INC.: COMPANY OVERVIEW  396

TABLE 392         MEDABLE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED              396

TABLE 393         MEDABLE INC.: PRODUCT/SERVICE LAUNCHES             396

TABLE 394         MEDABLE INC.: DEALS 397

14.1.8    MERATIVE L.P. 398

TABLE 395         MERATIVE L.P.: COMPANY OVERVIEW  398

TABLE 396         MERATIVE L.P.: PRODUCTS/SOLUTIONS/SERVICES OFFERED              398

14.1.9    PAREXEL INTERNATIONAL (MA) CORPORATION           399

TABLE 397         PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW        399

TABLE 398         PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED   399

TABLE 399         PARAXEL INTERNATIONAL (MA) CORPORATION: EXPANSIONS    400

14.1.10  CLIMEDO HEALTH GMBH         401

TABLE 400         CLIMEDO HEALTH GMBH: COMPANY OVERVIEW          401

TABLE 401         CLIMEDO HEALTH GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED          401

TABLE 402         CLIMEDO HEALTH GMBH: OTHER DEVELOPMENTS     401

14.1.11  HEALTHENTIA (A PRODUCT OF INNOVATION SPRINT)              402

TABLE 403         INNOVATION SPRINT: COMPANY OVERVIEW    402

TABLE 404         HEALTHENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED              402

14.1.12  VEEVA SYSTEMS            403

TABLE 405         VEEVA SYSTEMS: COMPANY OVERVIEW             403

FIGURE 54         VEEVA SYSTEMS: COMPANY SNAPSHOT (2022) 404

TABLE 406         VEEVA SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED          404

TABLE 407         VEEVA SYSTEMS: PRODUCT/SERVICE LAUNCHES          405

TABLE 408         VEEVA SYSTEMS: DEALS            405

14.1.13  ASSISTEK           406

TABLE 409         ASSISTEK: COMPANY OVERVIEW           406

TABLE 410         ASSISTEK: PRODUCTS/SOLUTIONS/SERVICES OFFERED              406

TABLE 411         ASSISTEK: DEALS           407

14.1.14  CUREBASE INC. 408

TABLE 412         CUREBASE INC.: COMPANY OVERVIEW 408

TABLE 413         CUREBASE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED              408

TABLE 414         CUREBASE INC.: OTHER DEVELOPMENTS          408

14.1.15  CASTOR             409

TABLE 415         CASTOR: COMPANY OVERVIEW             409

TABLE 416         CASTOR: PRODUCTS/SOLUTIONS/SERVICES OFFERED 409

TABLE 417         CASTOR: PRODUCT/SERVICE LAUNCHES          410

TABLE 418         CASTOR: OTHER DEVELOPMENTS        410

14.1.16  EVIDENTIQ GROUP GMBH        411

TABLE 419         EVIDENTIQ GROUP GMBH: COMPANY OVERVIEW         411

TABLE 420         EVIDENTIQ GROUP GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED   411

14.1.17  YPRIME, LLC     412

TABLE 421         YPRIME, LLC: COMPANY OVERVIEW     412

TABLE 422         YPRIME, LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED              412

TABLE 423         YPRIME, LLC: PRODUCT/SERVICE LAUNCHES   413

TABLE 424         YPRIME, LLC: DEALS     413

14.1.18  CLINICAL INK   414

TABLE 425         CLINICAL INK: COMPANY OVERVIEW   414

TABLE 426         CLINICAL INK: PRODUCTS/SOLUTIONS/SERVICES OFFERED              414

TABLE 427         CLINICAL INK: PRODUCT/SERVICE LAUNCHES & UPGRADES              415

TABLE 428         CLINICAL INK: DEALS   415

14.1.19  CLINION            416

TABLE 429         CLINION: COMPANY OVERVIEW            416

TABLE 430         CLINION: PRODUCTS/SOLUTIONS/SERVICES OFFERED              416

14.1.20  KAYENTIS         417

TABLE 431         KAYENTIS: COMPANY OVERVIEW          417

TABLE 432         KAYENTIS: PRODUCTS/SOLUTIONS/SERVICES OFFERED              417

TABLE 433         KAYENTIS: DEALS          418

TABLE 434         KAYENTIS: OTHER DEVELOPMENTS     418

14.2       OTHER PLAYERS           419

14.2.1    TRANSPERFECT             419

14.2.2    OBVIOHEALTH USA, INC.           419

14.2.3    WCG CLINICAL 420

14.2.4    СLINСAPTURE             420

14.2.5    CLOUDBYZ       421

*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

15          APPENDIX         422

15.1       DISCUSSION GUIDE      422

15.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             429

15.3       CUSTOMIZATION OPTIONS      431

15.4       RELATED REPORTS       431

15.5       AUTHOR DETAILS         432